Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2019, Article ID 5970659, 6 pages
https://doi.org/10.1155/2019/5970659
Research Article

Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy

Jia Yu,1,2,3,4 Gezhi Xu,1,2,3,4 Qing Chang,1,2,3,4 Xiaofeng Ye,1,2,3,4 Lei Li,1,2,3,4 Chunhui Jiang,1,2,3,4 and Qi Zhao5

1Department of Ophthalmology, Eye & Ear Nose Throat Hospital of Fudan University, Shanghai 200031, China
2Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200031, China
3NHC Key Laboratory of Myopia (Fudan University), Shanghai 200031, China
4Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai 200031, China
5Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China

Correspondence should be addressed to Qing Chang; moc.nuyila@gnahcgnq

Received 25 December 2018; Revised 23 May 2019; Accepted 11 June 2019; Published 14 August 2019

Academic Editor: Enrico Peiretti

Copyright © 2019 Jia Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Klais, M. D. Ober, A. P. Ciardella, and L. A. Yannuzzi, “Central serous chorioretinopathy,” in Retina, A. P. Schachat, Ed., vol. 2, pp. 1135–1161, Mosby, St. Louis, MO, USA, 4th edition, 2006. View at Google Scholar
  2. B. Nicholson, J. Noble, F. Forooghian, and C. Meyerle, “Central serous chorioretinopathy: update on pathophysiology and treatment,” Survey of Ophthalmology, vol. 58, no. 2, pp. 103–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Mrejen, C. Balaratnasingam, T. R. Kaden et al., “Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy,” Ophthalmology, vol. 126, no. 4, pp. 576–588, 2019. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fujita, Y. Imamura, K. Shinoda et al., “One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy,” Ophthalmology, vol. 122, no. 3, pp. 555–561, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-C. Tseng and S.-N. Chen, “Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy,” British Journal of Ophthalmology, vol. 99, no. 8, pp. 1070–1077, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. F. H. P. Lai, D. S. Ng, M. Bakthavatsalam et al., “A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy,” American Journal of Ophthalmology, vol. 170, pp. 91–99, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Haimovici, S. Koh, D. R. Gagnon, T. Lehrfeld, and S. Wellik, “Risk factors for central serous chorioretinopathy,” Ophthalmology, vol. 111, no. 2, pp. 244–249, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Chatziralli, S. A. Kabanarou, E. Parikakis, A. Chatzirallis, T. Xirou, and P. Mitropoulos, “Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study,” Current Eye Research, vol. 42, no. 7, pp. 1069–1073, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Ji, M. Li, X. Zhang, Y. Peng, and F. Wen, “Poor sleep quality is the risk factor for central serous chorioretinopathy,” Journal of Ophthalmology, vol. 2018, Article ID 9450297, 6 pages, 2018. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-K. Kim, S. J. Woo, K. H. Park, Y. K. Chi, J. W. Han, and K. W. Kim, “Association of central serous chorioretinopathy with psychosocial factors is dependent on its phase and subtype,” Korean Journal of Ophthalmology, vol. 32, no. 4, pp. 281–289, 2018. View at Publisher · View at Google Scholar
  11. E. Setrouk, B. Hubault, F. Vankemmel et al., “Circadian disturbance and idiopathic central serous chorioretinopathy,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 254, no. 11, pp. 2175–2181, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Bousquet, M. Dhundass, M. Lehmann et al., “Shift work: a risk factor for central serous chorioretinopathy,” American Journal of Ophthalmology, vol. 165, pp. 23–28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Daruich, A. Matet, L. Marchionno et al., “Acute central serous chorioretinopathy,” Retina, vol. 37, no. 10, pp. 1905–1915, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Matet, A. Daruich, M. Zola, and F. Behar-Cohen, “Risk factors for recurrences of central serous chorioretinopathy,” Retina, vol. 38, no. 7, pp. 1403–1414, 2018. View at Publisher · View at Google Scholar · View at Scopus
  15. D. R. Guyer, L. A. Yannuzzi, J. S. Slakter, J. A. Sorenson, A. Ho, and D. Orlock, “Digital indocyanine green videoangiography of central serous chorioretinopathy,” Archives of Ophthalmology, vol. 112, no. 8, pp. 1057–1062, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Haimovici, S. Rumelt, and J. Melby, “Endocrine abnormalities in patients with central serous chorioretinopathy,” Ophthalmology, vol. 110, no. 4, pp. 698–703, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. https://pubs.niaaa.nih.gov/publications/Practitioner/pocketguide/pocket_guide2.htm.
  18. C. Bastien, A. Vallières, and C. M. Morin, “Validation of the insomnia severity index as an outcome measure for insomnia research,” Sleep Medicine, vol. 2, no. 4, pp. 297–307, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Morin, G. Belleville, L. Bélanger, and H. Ivers, “The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response,” Sleep, vol. 34, no. 5, pp. 601–608, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. R. F. Spaide, L. Campeas, A. Haas et al., “Central serous chorioretinopathy in younger and older adults,” Ophthalmology, vol. 103, no. 12, pp. 2070–2080, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Spitznas and J. Huke, “Number, shape, and topography of leakage points in acute type I central serous retinopathy,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 225, no. 6, pp. 437–440, 1987. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Hanumunthadu, E. H. C. Van Dijk, S. Gangakhedkar et al., “Gender variation in central serous chorioretinopathy,” Eye, vol. 32, no. 11, pp. 1703–1709, 2018. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Yildiz and M. Seyrek, “Vasodilating mechanisms of testosterone,” Experimental and Clinical Endocrinology & Diabetes, vol. 115, no. 1, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. S. Hayreh, “In vivo choroidal circulation and its watershed zones,” Eye, vol. 4, no. 2, pp. 273–289, 1990. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Nudleman, M. T. Witmer, S. Kiss, G. A. Williams, and J. D. Wolfe, “Central serous chorioretinopathy in patients receiving exogenous testosterone therapy,” Retina, vol. 34, no. 10, pp. 2128–2132, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Çiloğlu, F. Unal, and N. C. Dogan, “The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 256, no. 6, pp. 1111–1116, 2018. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Forooghian, A. D. Meleth, C. Cukras, E. Y. Chew, W. T. Wong, and C. B. Meyerle, “Finasteride for chronic central serous chorioretinopathy,” Retina, vol. 31, no. 4, pp. 766–771, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Moisseiev, A. J. Holmes, A. Moshiri, and L. S. Morse, “Finasteride is effective for the treatment of central serous chorioretinopathy,” Eye, vol. 30, no. 6, pp. 850–856, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Bousquet, T. Beydoun, P.-R. Rothschild et al., “Spironolactone for nonresolving central serous chorioretinopathy,” Retina, vol. 35, no. 12, pp. 2505–2515, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Rahimy, J. D. Pitcher III, J. Hsu et al., “A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ECSELSIOR),” Retina, vol. 38, no. 5, pp. 962–969, 2018. View at Publisher · View at Google Scholar · View at Scopus
  31. P. M. Seferovic, F. Pelliccia, I. Zivkovic et al., “Mineralocorticoid receptor antagonists, a class beyond spironolactone—focus on the special pharmacologic properties of eplerenone,” International Journal of Cardiology, vol. 200, pp. 3–7, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. M. G. Ersoz, S. Arf, M. Hocaoglu, I. Sayman Muslubas, and M. Karacorlu, “Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients,” British Journal of Ophthalmology, vol. 103, no. 6, pp. 725–729, 2018. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Rashid, S. K. Bhatia, K. I. Mazzitello et al., “RPE cell and sheet properties in normal and diseased eyes,” Retinal Degenerative Diseases, vol. 854, pp. 757–763, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Gouras, L. Ivert, M. Neuringer, and T. Nagasaki, “Mitochondrial elongation in the macular RPE of aging monkeys, evidence of metabolic stress,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 254, no. 6, pp. 1221–1227, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Chen, D. Rajapakse, M. Fraczek, C. Luo, J. V. Forrester, and H. Xu, “Retinal pigment epithelial cell multinucleation in the aging eye—a mechanism to repair damage and maintain homoeostasis,” Aging Cell, vol. 15, no. 3, pp. 436–445, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Meerlo, A. Sgoifo, and D. Suchecki, “Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity,” Sleep Medicine Reviews, vol. 12, no. 3, pp. 197–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Daruich, A. Matet, A. Dirani et al., “Central serous chorioretinopathy: recent findings and new physiopathology hypothesis,” Progress in Retinal and Eye Research, vol. 48, pp. 82–118, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Zakir, M. Shukla, Z.-U.-R. Simi, J. Ahmad, and M. Sajid, “Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy,” Indian Journal of Ophthalmology, vol. 57, no. 6, pp. 419–422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. H. A. Tufan, B. Gencer, and A. T. Comez, “Serum cortisol and testosterone levels in chronic central serous chorioretinopathy,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 251, no. 3, pp. 677–680, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. S. P. Garg, T. Dada, D. Talwar, and N. R. Biswas, “Endogenous cortisol profile in patients with central serous chorioretinopathy,” British Journal of Ophthalmology, vol. 81, no. 11, pp. 962–964, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. C. J. Eriksson, “The role of acetaldehyde in the actions of alcohol (update 2000),” Alcoholism: Clinical and Experimental Research, vol. 25, no. S1, pp. 15S–32S, 2001. View at Publisher · View at Google Scholar
  42. H. M. Kang, Y. J. Woo, H. J. Koh, C. S. Lee, and S. C. Lee, “The effect of consumption of ethanol on subfoveal choroidal thickness in acute phase,” British Journal of Ophthalmology, vol. 100, no. 3, pp. 383–388, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Ozkaya, Z. Alkin, M. Ozveren, A. T. Yazici, and M. Taskapili, “The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study,” Eye, vol. 30, no. 7, pp. 1005–1010, 2016. View at Publisher · View at Google Scholar · View at Scopus